Escitalopram Leads Study on Preventing Depression Relapse
A major analysis of nearly 10,000 patients finds escitalopram most effective at preventing depression relapse, with agomelatine and duloxetine also performing well. Experts stress the differences are modest and individual factors are key.

A new study on escitalopram effectiveness in preventing depression relapse has found it outperforms other common antidepressants. Published in The Lancet Psychiatry, the analysis of nearly 10,000 patients prescribed medication for up to a year showed escitalopram was best at keeping symptoms from returning.
Fluoxetine, also known as Prozac, performed well but ranked just below escitalopram, agomelatine, and duloxetine. Patients taking escitalopram were also less likely to stop their medication compared to those on fluoxetine. The research compared more than a dozen commonly prescribed drugs, finding others like sertraline did not demonstrate the same advantages. Depression is a widespread condition, affecting around one in six people in the UK.
Other antidepressants show varying effectiveness
After escitalopram, the medications agomelatine and duloxetine ranked next in effectiveness for preventing relapse. Sertraline was found to be no better than other medications in the study. The findings provide a broad comparison of how different antidepressants perform over time.
Doctors emphasize individualized treatment decisions
Experts caution that the observed differences in effectiveness are modest. They are unlikely to outweigh individual factors like side effects, a patient's previous response to medication, and personal preference. Professor Allan Young from the Royal College of Psychiatrists emphasized that individual circumstances remain most important when deciding which antidepressant to prescribe.
Escitalopram belongs to the selective serotonin reuptake inhibitor (SSRI) class, which increases serotonin linked to mood improvement. SSRIs like escitalopram, sertraline, and fluoxetine are commonly recommended as first-line treatments. The NHS states that if an SSRI is ineffective or unsuitable, doctors may recommend trying a different type, such as an SNRI. Older tricyclic antidepressants like amitriptyline are now less commonly prescribed.
Handling treatment and side effects
Doctors recommend staying on antidepressants for at least six months after depression ends to help prevent a relapse. However, the mental health charity Mind notes it is common for people to need to try more than one medication before finding the right treatment. Dr Sameer Jauhar from Imperial College London warned the research has limits, stating, "it cannot tell us which antidepressant will work best for an individual patient."
Side effects are a key consideration. Escitalopram can cause sleep problems, constipation, and weight gain. Mind adds that people need access to clear information about antidepressant benefits, side effects, and other support options like talking therapies. Researchers acknowledge that longer studies are needed to better understand differences between antidepressants over time. Professor Eric Ruhé from Radboud University in the Netherlands said the study helps inform prescribers' and patients' decisions on choosing a medication that keeps patients well.
Dr Jauhar advises that patients should continue their current treatment if they are responding well, as changing medication without evidence may cause harm.





